1-5 of 5
E. Hellstrom-Lindberg
Close
Sort by
Journal Articles

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Clinical Trials & Observations
U. Platzbecker, P. Fenaux, L. Adès, A. Giagounidis, V. Santini, A. A. van de Loosdrecht, D. Bowen, T. de Witte, G. Garcia-Manero, E. Hellström-Lindberg, U. Germing, R. Stauder, L. Malcovati, Mikkael A. Sekeres, David P. Steensma, S. Gloaguen
Journal: Blood
Blood (2019) 133 (10): 1020–1030.
https://doi.org/10.1182/blood-2018-06-857102
Published: 2019
Journal Articles

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, MD, G.J. Mufti, MD, V. Santini, MD, C. Finelli, MD, A. Giagounidis, MD, R. Schoch, MD, A.F. List, MD, S.D. Gore, MD, J.F. Seymour, MD, E. Hellstrom-Lindberg, MD, J.M. Bennett, MD, J.C. Byrd, MD, J.T. Backstrom, MD, L.S. Zimmerman, BSN, D.R. McKenzie, MS, C.L. Beach, PharmD, L.R. Silverman, MD
Journal: Blood
Blood (2007) 110 (11): 817.
https://doi.org/10.1182/blood.V110.11.817.817
Published: 2007
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.

M. Oosterveld, MD, S. Suciu, M.Sc, P. Muus, MD, M. Delforge, MD, A. Belhabri, MD, C. Aul, MD, D. Selleslag, MD, A. Ferrant, MD, J.-P. Marie, MD, S. Amadori, MD, U. Jehn, MD, U. Hess, MD, R. Willemze, MD, E. Hellstrom-Lindberg, MD, M. Vignetti, MD, B. Labar, MD, F. Mandelli, MD, T. De Witte, MD
Journal: Blood
Blood (2004) 104 (11): 2020.
https://doi.org/10.1182/blood.V104.11.2020.2020
Published: 2004
Journal Articles

Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS).

S. Brechignac, E. Hellstrom-Lindberg, D. T. Bowen, T. M. DeWitte, M. Cazzola, P. Fenaux
Journal: Blood
Blood (2004) 104 (11): 4716.
https://doi.org/10.1182/blood.V104.11.4716.4716
Published: 2004